Tekla Capital Management LLC continued to hold its position in uniQure N.V. (NASDAQ:QURE) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 241,021 shares of the biotechnology company’s stock at the end of the second quarter. Tekla Capital Management LLC owned approximately 0.95% of uniQure N.V. worth $1,492,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the stock. FMR LLC grew its position in uniQure N.V. by 4.1% in the 2nd quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after buying an additional 61,650 shares during the last quarter. JPMorgan Chase & Co. grew its position in uniQure N.V. by 33.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after buying an additional 14,659 shares during the last quarter. Paloma Partners Management Co grew its position in uniQure N.V. by 717.7% in the 1st quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock valued at $491,000 after buying an additional 74,605 shares during the last quarter. Weiss Multi Strategy Advisers LLC grew its position in uniQure N.V. by 266.7% in the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 55,000 shares of the biotechnology company’s stock valued at $318,000 after buying an additional 40,000 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in uniQure N.V. by 48.8% in the 1st quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock valued at $2,162,000 after buying an additional 122,700 shares during the last quarter. Hedge funds and other institutional investors own 29.86% of the company’s stock.

A number of research firms recently weighed in on QURE. ValuEngine upgraded shares of uniQure N.V. from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Zacks Investment Research upgraded shares of uniQure N.V. from a “sell” rating to a “hold” rating and set a $9.25 price objective on the stock in a research report on Wednesday, August 9th. Chardan Capital set a $13.00 price objective on shares of uniQure N.V. and gave the company a “buy” rating in a research report on Sunday, July 23rd. Finally, Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $17.00 price objective on shares of uniQure N.V. in a research report on Friday, June 30th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $12.45.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.watchlistnews.com/tekla-capital-management-llc-has-1492000-holdings-in-uniqure-n-v-qure/1598930.html.

uniQure N.V. (NASDAQ:QURE) traded up 5.84% during midday trading on Friday, reaching $9.60. The company’s stock had a trading volume of 166,680 shares. The company’s market capitalization is $245.38 million. uniQure N.V. has a 1-year low of $4.72 and a 1-year high of $9.81. The company’s 50-day moving average price is $8.22 and its 200-day moving average price is $6.48.

uniQure N.V. (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by ($0.05). uniQure N.V. had a negative return on equity of 131.27% and a negative net margin of 289.94%. The business had revenue of $4.94 million during the quarter, compared to the consensus estimate of $2.92 million. On average, analysts predict that uniQure N.V. will post ($3.06) earnings per share for the current fiscal year.

uniQure N.V. Company Profile

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Institutional Ownership by Quarter for uniQure N.V. (NASDAQ:QURE)

Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.